Press release - 24 September 2019
Barwon Completes co-investment in Kent Pharmaceuticals
24 September 2019
Barwon Investment Partners is pleased to announce the successful completion of a co-investment in UK and Ireland based generic pharmaceuticals business Kent Pharmaceuticals. The investment has been made alongside highly-regarded UK private equity manager Duke Street. Duke Street led the buyout supported by existing Chief Executive of Kent Pharmaceuticals, Debashis Dasgupta, who has previous experience at pharmaceuticals companies including Sanofi and Ranbaxy.
Kent Pharmaceuticals is corporate carve-out from FTSE 100 constituent conglomerate DCC plc.
Barwon has now successfully completed a number of private equity co-investments on behalf of wholesale and institutional clients. Previous successful co-investments have included German river-cruise business A-Rosa, and Chicago-based trucking business Mr Bults Inc.
Founding Partner and Head of Private Equity at Barwon, Sam Armstrong, commented: “We are very pleased to be making another co-investment alongside Duke Street, who have done a wonderful job on previous investments, including A-Rosa. Private equity can be a difficult asset class for all but the very largest investors to get access to. We are delighted that we have been able to structure these investments to allow wholesale investors to benefit from these higher returning investment strategies.”
Barwon Investment Partners is a Sydney-based alternative asset manager, with total assets under management of approximately A$1.5bn. In addition to private equity co-investments, Barwon manages portfolios of listed private equity assets, private debt and healthcare real estate assets.
For more information please contact James Brown at Barwon Investment Partners on (02) 9216-9608.